# A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease

> **NCT07111013** · PHASE3 · WITHDRAWN · sponsor: **Bausch & Lomb Incorporated**

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** Lifitegrast/perfluorohexyloctane (PFHO)

## Key facts

- **NCT ID:** NCT07111013
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-12
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business Decision
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07111013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07111013, "A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07111013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*